Literature DB >> 25446762

The rotenone-induced rat model of Parkinson's disease: behavioral and electrophysiological findings.

Christof von Wrangel1, Kerstin Schwabe1, Nadine John1, Joachim K Krauss1, Mesbah Alam2.   

Abstract

Exposure to rotenone leads to parkinsonian features, such as loss of dopaminergic neurons in the substantia nigra and motor impairment, however, the validity of this model has recently been questioned. In rodent and monkey models of Parkinson's disease (PD) abnormal neuronal activity in the basal ganglia motor loop has been described, with hyperactivity of the subthalamic nucleus (STN) similar to that found in PD. The present study aims at providing new and more specific evidence for the validity of the rotenone rat model of PD by examining whether neuronal activity in the STN is altered. Male Sprague Dawley rats were treated with rotenone injections (2.5mg/kg bodyweight intraperitoneally) for 60 days. Behavioral analysis showed an impairment in the rotarod and hanging wire test in the rotenone group (p<0.05), accompanied by a decline in tyrosine hydroxylase immunoreactive neurons in the nigro-striatal region (p<0.001). Thereafter, single unit (SU) activities and local field potentials were recorded in the STN in urethane anesthetized rats. The SU analysis revealed a higher neuronal discharge rate (p<0.001), more bursts per minute (p=0.006) and a higher oscillatory activity (p=0.008) in the STN of rotenone treated rats. Spectral analysis showed an increase of relative beta power in the STN as well as in the motor cortex. We found electrophysiological key features of PD pathology and pathophysiology in the STN of rotenone treated rats. Therefore, the rotenone-induced rat model of PD deserves further attention since it covers more aspects than dopamine depletion and implies the reproducibility of PD specific features.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Local field potentials; Mitochondrial complex I; Parkinson's disease; Rotenone; Single unit activity; Subthalamic nucleus

Mesh:

Substances:

Year:  2014        PMID: 25446762     DOI: 10.1016/j.bbr.2014.11.002

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  18 in total

1.  Neuronal Entropy-Rate Feature of Entopeduncular Nucleus in Rat Model of Parkinson's Disease.

Authors:  Olivier Darbin; Xingxing Jin; Christof Von Wrangel; Kerstin Schwabe; Atsushi Nambu; Dean K Naritoku; Joachim K Krauss; Mesbah Alam
Journal:  Int J Neural Syst       Date:  2015-10-06       Impact factor: 5.866

2.  Coherence of neuronal firing of the entopeduncular nucleus with motor cortex oscillatory activity in the 6-OHDA rat model of Parkinson's disease with levodopa-induced dyskinesias.

Authors:  Xingxing Jin; Kerstin Schwabe; Joachim K Krauss; Mesbah Alam
Journal:  Exp Brain Res       Date:  2016-01-02       Impact factor: 1.972

3.  Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal α-synuclein preformed fibrils.

Authors:  Joseph R Patterson; Megan F Duffy; Christopher J Kemp; Jacob W Howe; Timothy J Collier; Anna C Stoll; Kathryn M Miller; Pooja Patel; Nathan Levine; Darren J Moore; Kelvin C Luk; Sheila M Fleming; Nicholas M Kanaan; Katrina L Paumier; Omar M A El-Agnaf; Caryl E Sortwell
Journal:  Neurobiol Dis       Date:  2019-07-02       Impact factor: 5.996

4.  DL-3-n-butylphthalide alleviates motor disturbance by suppressing ferroptosis in a rat model of Parkinson's disease.

Authors:  Chun-Bo Hu; Hui Jiang; Yin Yang; Guo-Hua Wang; Qiu-Hong Ji; Zhong-Zheng Jia; Li-Hua Shen; Qian-Qian Luo
Journal:  Neural Regen Res       Date:  2023-01       Impact factor: 6.058

5.  Improved neuroprotective effect of resveratrol nanoparticles as evinced by abrogation of rotenone-induced behavioral deficits and oxidative and mitochondrial dysfunctions in rat model of Parkinson's disease.

Authors:  Suresh Palle; Prasad Neerati
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-02-06       Impact factor: 3.000

Review 6.  Alpha-Synuclein as a Biomarker of Parkinson's Disease: Good, but Not Good Enough.

Authors:  Upasana Ganguly; Sukhpal Singh; Soumya Pal; Suvarna Prasad; Bimal K Agrawal; Reena V Saini; Sasanka Chakrabarti
Journal:  Front Aging Neurosci       Date:  2021-07-08       Impact factor: 5.750

7.  Nanotechnology-based drug delivery of ropinirole for Parkinson's disease.

Authors:  Emilia Barcia; Liudmila Boeva; Luis García-García; Karla Slowing; Ana Fernández-Carballido; Yaquelyn Casanova; Sofía Negro
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

8.  Imaging and Quantitative Analysis of the Interstitial Space in the Caudate Nucleus in a Rotenone-Induced Rat Model of Parkinson's Disease Using Tracer-based MRI.

Authors:  Deyong Lv; Jingbo Li; Hongfu Li; Yu Fu; Wei Wang
Journal:  Aging Dis       Date:  2017-02-01       Impact factor: 6.745

9.  Adenosine A2A Receptor Blockade Prevents Rotenone-Induced Motor Impairment in a Rat Model of Parkinsonism.

Authors:  Ahmed M Fathalla; Amira M Soliman; Mohamed H Ali; Ahmed A Moustafa
Journal:  Front Behav Neurosci       Date:  2016-02-29       Impact factor: 3.558

10.  Therapeutic effects of baicalein on rotenone-induced Parkinson's disease through protecting mitochondrial function and biogenesis.

Authors:  Xue Zhang; Lida Du; Wen Zhang; Yulin Yang; Qimeng Zhou; Guanhua Du
Journal:  Sci Rep       Date:  2017-08-30       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.